Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lonafarnib in Recurrent Head and Neck Cancer
NCT00073450Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Sep 2003
- Primary completion
- Jun 2004
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of lonafarnib in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Merck & Co. Primary endpoint: Objective Response Rate. Started Sep 2003; status: terminated.
02
Drugs
lonafarnib
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT00073450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00073450.